- Previous Close
11.77 - Open
11.76 - Bid 10.81 x 200
- Ask 12.51 x 200
- Day's Range
11.45 - 11.79 - 52 Week Range
10.71 - 17.08 - Volume
442,445 - Avg. Volume
1,084,449 - Market Cap (intraday)
3.332B - Beta (5Y Monthly) 1.93
- PE Ratio (TTM)
73.47 - EPS (TTM)
0.16 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
15.07
Sotera Health Company provides sterilization, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for the medical device, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
soterahealth.com3,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SHC
View MorePerformance Overview: SHC
Trailing total returns as of 3/31/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHC
View MoreValuation Measures
Market Cap
3.34B
Enterprise Value
5.41B
Trailing P/E
73.56
Forward P/E
15.90
PEG Ratio (5yr expected)
1.33
Price/Sales (ttm)
3.05
Price/Book (mrq)
8.24
Enterprise Value/Revenue
4.92
Enterprise Value/EBITDA
12.23
Financial Highlights
Profitability and Income Statement
Profit Margin
4.03%
Return on Assets (ttm)
6.76%
Return on Equity (ttm)
10.46%
Revenue (ttm)
1.1B
Net Income Avi to Common (ttm)
44.34M
Diluted EPS (ttm)
0.16
Balance Sheet and Cash Flow
Total Cash (mrq)
278.05M
Total Debt/Equity (mrq)
580.53%
Levered Free Cash Flow (ttm)
107.18M